Cyp Substrates + Epcoritamab Bysp Interaction
Moderateinteraction on record
Description
Epcoritamab-bysp causes cytokine release that may suppress CYP enzyme activity, resulting in increased exposure of CYP substrates. This is more likely after the first dose and up to 14 days after the first 48 mg dose, and during/after CRS.
Mechanism
Cytokine-mediated suppression of CYP enzyme activity
Source: NLP:epcoritamab-bysp